|
［1］Williams TM,Lisanti MP. Protein family review: The caveolin proteins［J］. Genome Biol, 2004, 5(3): 214.
［2］Patra SK,Bettuzzi S.Epigenetic DNAmethylation regulation of genes coding for lipid raftassociated components: A role for raft proteins in cell trans formation and cancer progression(Review)［J］. Oncol Reports, 2007, 17(6): 12791290.
［3］Zajchowski LD，Robbins SM. Lipid rafts and little caves．Compartmentalized signalling in membrane microdomains［J］．Eur J Biochem，2002，269(3)：737752.
［4］Mukherjee S,Maxfield FR.Role of membrane organization and membrane domains in endocytic lipid trafficking［J］．Trafic，2000，1(3)：203211.
［5］Clarke CJ, Forman S. Phospholipase Cδ1 modulates sus tained contraction of rat mesenteric small arteries in response to noradrenaline, but not endothelin1［J］. Am J Physiol Heart Circ Physiol,2008,295(2):826834.
［6］Doherty GJ, McMahon HT. Mechanisms of endocytosis［J］. Annu Rev Biochem, 2009, 78: 857902.
［7］Liu XQ, Thangavel M. Adenylyl cyclase Type 6 overexpression selectively enhances βadrenergic and prostacyclin receptormediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts［J］. NaunynSchmiedebergs Arch Pharmacol, 2008, 377(46): 359369.
［8］Sessa WC. Regulation of endothelial derived nitric oxide in health and disease［J］. Mem Inst Oswaldo Cruz Rio de Janeiro, 2005, 100（Suppl 1）: 1518.
［9］Gratton JP, Fontana J. Reconstitution of an endothelial nitricoxide synthase (eNOS), hsp90, and caveolin1 complex in Vitro［J］. J Biol Chem, 2000, 275(29):2226822272.
［10］Dudzinski DM, Michel T. Life history of eNOS: Partners and path ways［J］. Cardiovasc Res, 2007,75(2): 247260.
［11］Razani B, Engelman JA, Wang XB, et al. Caveolin1 nullmice are viable, but show evidence of hyperproliferative an d vascular abnormalities［J］. J Biol Chem, 2001, 276(41): 3812138138.
［12］Jung SY, Kwak JO, Kim HW, et al. Calcium sensing receptor forms complex with and is upregulated by caveolin1 in cultured human osteosarcoma(Saos2) cells ［J］. Exp Mol Med, 2005, 37(2): 91100.
［13］TfeltHansen J, Hansen JL, Smajilovic S, et al. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes［J］. Am J Physiol Heart Circ Physiol, 2006, 290(3): 11651171.
［14］Smajilovic S, Hansen JL, Christoffersen TE, et al. Extracellar calcium sensing in rat atrtic vascular smooth muscle cells［J］. Biochem Biophys Res Commun, 2006, 348(4): 12151223.
［15］Weston AH, Absi M,Ward DT, et al. Evidence in favor of a calciumsensing receptor in arterial endothelial cells: studies with calindol and Calhex 231［J］. Circ Res, 2005, 97(4): 391398.
［16］Wu ZZ, Tandon R, Ziembicki J, et al. Role of ceramide in Ca2+sensing receptorinduced apoptosis［J］. J Lipid Res, 2005, 46(7): 13961404.
［17］Jin S, Zhang Y, Yi F, et al. Critical role of lipid raft redox signaling platforms in endostatininduced coronary endothelial dysfunction［J］. Arterioscler Thromb Vasc Biol, 2008, 28(3): 485490.
［18］Ju H，Behm DJ, Nerorkar S, et al. p38MAPK inhibitors ameliorate target organ damage in hypertension:Part1 p38 MAPK dependent endothelial dysfunction and hypertension［J］. J Pharmacol Exp Ther, 2003, 307(3): 932938.
［19］Taniyama Y，UshioFukai M. Role of p38 MAPK and MAPK2 in angiotensinⅡ induced akt activation in vascular smooth muscle cells［J］. Am J Physiol, 2004, 287(2): 494499.
［20］Mineo C, James GL, Smart EJ, et al. Localization of epidermal growth factor stimulated Rad/Raf interaction to caveolae membrane［J］. J Biol Chem, 1996, 271(20): 11930935.
［21］Francesconi A, Kumari R, Zukin RS. Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway ［J］. J Neurosci, 2009, 29 (11):35903602.
［22］Suthanthitan M, Li B, Song JO, et al. Transforming growth factorβ1 hyperexpression in African—American hypertensive: a novel mediator of hypertension and／or target organ damage［J］．Proc Natl Acad Sci USA, 2000, 97(7): 34793484．
［23］Schwartz EA, Reaven E. Transforming growth factorβ receptors localize to caveolae and regulate endothelial nitric oxide synthase in normal human endothelial cells［J］. Biochem J, 2005, 390(Pt 1): 199206.
［24］Han WX, Li HW, Villar VA, et al．Lipid rafts keep NADPH oxidase in the inactive state in human renal proximal tubule cells［J］．Hypertension, 2008, 51(2): 481487.
［25］UshioFukai M, Zuo L, Ikeda S, et al. cAb1 tyrosine kinase mediates reactive oxygen species and caveolindependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy［J］. Circ Res, 2005, 97(8): 829836.
［26］Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensinⅡ uncoupling of endothelial nitric oxide synthase［J］. Proc Natl Acad Sci USA, 2005, 102(25): 90569061.
［27］Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?［J］. Am J Physiol Regul Integr Comp Physiol, 2005, 289(4): R913R935.
［28］Salanueva IJ, Cerezo A, Guadamillas MC, et al. Integrin regulation of caveolin function［J］. Cell Mol Med, 2007, 11(5): 969980.
［29］Higashi M, Mukai Y, Matoba T, et al． Longterm inhibition of Rhokinase suppresses angiotensin Ⅱinduced formation of coronary vascular lesions and cardiac hypertrophy in rats in vivo［J］．Cireulation, 2001, 104(suppl II): 325．
［30］Tsujikawa H, Song YM, Watanabe M, et al. Cholesterol depletion modulates basal Ltype Ca2+ current and abolishes its βadrenergic enhancement in ventricular myocytes［J］. Am J Physiol Heart Circ Physiol, 2008, 294(1): 285292.
［31］Kikuchi T, Oka N, Koga A, et al. Behavior of caveolae and ceaveolin3 during the development of myoeyte hypertrophy［J］．J Cardiovasc Pharmacol, 2005, 45(3): 204210．
［32］Yamamoto M, Toya Y, Schwencke C, et al. Caveolin is an activator of insulin receptor signaling［J］. J Biol Chem, 1998, 273(41): 2696226968.
［33］Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: Disturbance of the regulatory system consisting of humoral and neuronal signais［J］．Circ Res, 2007, 101(1):2739.
［34］Strazzullo P，Barbato A，Galletti F, et al．Abnormalities of renal sodium handling in the metabolic syndrome: Results of the olivetti heart study［J］．J Hypertens, 2006, 24 (8):16331639. |
